Sign inSubscribe

target directory

anemia associated with chronic kidney disease clinical trial intelligence

Trials are included when the normalized target field matches this target directory. Full protocol, result, eligibility and IP analysis is available inside the premium workspace.

Validated reports

1

Directory type

target

Association rule

normalized field

NCT01587898
Source recordAI-normalized

A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis

The study evaluated GSK1278863, a prolyl hydroxylase inhibitor, for treating anemia in patients with chronic kidney disease not on dialysis. Conducted by GlaxoSmithKline, the trial involved 72 participants and aimed to assess safety, efficacy, and pharmacokinetics over four weeks.

AI analysis

Indication: Anaemia

Modality: small molecule

Target: Anemia associated with Chronic Kidney Disease

Sponsor: GlaxoSmithKline

Source URL: ClinicalTrials.gov

Source updated: Nov 09, 2017

Ingested: May 30, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: Anemia associated with Chronic Kidney Disease

View original source fields

Condition raw: Anaemia

Condition normalized: Anaemia

Modality raw: Anaemia

Modality normalized: small molecule

Target raw: Anemia associated with Chronic Kidney Disease

Target normalized: Anemia associated with Chronic Kidney Disease

Open report